BACKGROUND: BioGlue (Cryolife Inc, Kennesaw GA) was introduced as an alternative tissue sealant. Its most common application has been in repairs of acute dissections of the aorta. There is no reported experience with its use in the repair of intracardiac structural defects. METHODS: In 5 patients BioGlue was used as an adjunct in repairs of complex intracardiac structural defects. It was used during patch repair of posterior mitral annular defects in 2 patients and aortic annular defect in 1 patient in the presence of active endocarditis. It was also used in 1 patient with a chronic atrioventricular groove pseudoaneurysm following mitral valve replacement, and in 1 patient during repair of a postinfarction posterior ventricular septal rupture. RESULTS: There were no hospital or late deaths. Immediate intraoperative transesophageal echocardiography and late follow-up echocardiography documented complete and durable repair of all defects without recurrence. At follow-up all patients are in New York Heart Association class I-II, 6 to 29 months postoperatively. No patient has suffered late complications or exhibited signs of glue embolization. CONCLUSIONS: BioGlue was found to be an effective adjuvant to the standard techniques used for the repair of intracardiac structural defects of various etiologies. Long-term follow-up is recommended to determine its long-term safety in this application.
BACKGROUND: BioGlue (Cryolife Inc, Kennesaw GA) was introduced as an alternative tissue sealant. Its most common application has been in repairs of acute dissections of the aorta. There is no reported experience with its use in the repair of intracardiac structural defects. METHODS: In 5 patients BioGlue was used as an adjunct in repairs of complex intracardiac structural defects. It was used during patch repair of posterior mitral annular defects in 2 patients and aortic annular defect in 1 patient in the presence of active endocarditis. It was also used in 1 patient with a chronic atrioventricular groove pseudoaneurysm following mitral valve replacement, and in 1 patient during repair of a postinfarction posterior ventricular septal rupture. RESULTS: There were no hospital or late deaths. Immediate intraoperative transesophageal echocardiography and late follow-up echocardiography documented complete and durable repair of all defects without recurrence. At follow-up all patients are in New York Heart Association class I-II, 6 to 29 months postoperatively. No patient has suffered late complications or exhibited signs of glue embolization. CONCLUSIONS: BioGlue was found to be an effective adjuvant to the standard techniques used for the repair of intracardiac structural defects of various etiologies. Long-term follow-up is recommended to determine its long-term safety in this application.
Authors: Wei-Guo Ma; Bulat A Ziganshin; Chang-Fa Guo; Mohammad A Zafar; Richard S Sieller; Maryann Tranquilli; John A Elefteriades Journal: J Thorac Dis Date: 2017-08 Impact factor: 2.895
Authors: Ahmet Baris Durukan; Fatih Tanzer Serter; Hasan Alper Gurbuz; Murat Tavlasoglu; Halil Ibrahim Ucar; Cem Yorgancioglu Journal: J Tehran Heart Cent Date: 2014-07-03
Authors: Davide Pacini; Giacomo Murana; David Hollinworth; William F Northrup; Stacy G Arnold; Roberto Di Bartolomeo Journal: Front Surg Date: 2022-09-09